BHC(SH:600721) Sou Hu Cai Jing·2025-08-05 12:29Group 1 - The core viewpoint of the news is that Baihua Pharmaceutical (600721) has shown a slight decline in stock price and has experienced significant net outflow of funds, indicating potential investor concerns [1] - As of August 5, 2025, Baihua Pharmaceutical's stock closed at 8.2 yuan, down 0.85%, with a turnover rate of 4.61% and a trading volume of 177,200 hands, amounting to 146 million yuan [1] - The latest financial performance for Baihua Pharmaceutical shows total revenue of 96.91 million yuan for Q1 2025, a year-on-year increase of 6.65%, while net profit attributable to shareholders was 20.72 million yuan, up 0.28% year-on-year [1] Group 2 - The company has a current liquidity ratio of 1.979, a quick ratio of 1.624, and a debt-to-asset ratio of 30.45%, indicating a stable financial position [1] - Baihua Pharmaceutical has made investments in 12 external companies and participated in 16 bidding projects, showcasing its active engagement in business expansion [2] - The company holds 16 trademark registrations and has obtained 6 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]